

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

Orlistat

Product Number **O 4139** Storage Temperature 2-8 °C

CAS RN: 96829-58-2

Synonyms: Ro-18-0647; (-)-Tetrahydrolipstatin; N-formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester

Molecular Formula: C₂₉H₅₃NO₅ Molecular Weight: 495.73

Product Description

Orlistat, an anti-obesity agent, acts locally in the gastrointestinal tract to inhibit lipase, an enzyme that is necessary for the digestion of long-chain triglycerides.¹

It is minimally absorbed and helps reduce body weight by inhibiting absorption of ingested dietary fat by approximately 30%. It can be a useful adjunctive therapy for weight loss and maintenance in obese patients willing to undergo changes in diet and exercise routines.²

Orlistat can also impact cardiovascular risk factors including total and low-density lipoprotein cholesterol, blood pressure and plasma glucose when accompanied by dietary changes.¹

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Soluble in DMSO at 19 mg/mL

Storage/Stability

Store at 2-8 °C.

References

- 1. Ballinger, A. and Peikin, S.R., Orlistat: Its current status as an anti-obesity drug., Eur. J. Pharmacol., **440**, 109-17 (2002).
- 2. Lucas, K. H., et. al., Orlistat—a novel weight loss therapy. Ann. Pharmacother. **35**, 314-328 (2001).
- 3. Wieland, H.A. and Hamilton, B.S., Weighing the options in the pharmacotherapy of obesity. Int. J. Clin. Pharmacol. Ther., **39**, 406-414 (2001).
- 4. Hauptman, J., et al., Orlistat in the long-term treatment of obesity in primary care settings., Arch. Fam. Med., **9**, 160-167 (2000).

AH/PHC 11/04